Accessibility Accessibility icon
CONSULTATION (303) 951-5829
Accent Image
Introducing XEOMIN:  The Latest Treatment for Facial Aging

Introducing XEOMIN: The Latest Treatment for Facial Aging

December 8, 2011

As if you weren’t already confused about which injectable to choose, the FDA recently approved a new competitor to Botox. This new kid on the block goes by the name Xeomin and is brought to you by the same company that manufactures the filler injectable, Radiesse. So what’s the big deal and will Xeomin be any better than it’s currently available alternative Botox?

All neuromodulators, such as Botox, share a common core protein. This single protein is responsible for blocking the message from the nerve telling the muscle to fire. The result is that the muscle does not receive the message; the muscle doesn’t contract, and over time the skin overlying this muscle relaxes and its wrinkles soften and often go away completely. What differentiate the various products are the additional proteins surrounding this central core. These accessory proteins affect specific qualities of the injectable such as how many days it requires to take effect, how long it lasts, and it’s potential for local diffusion. And this is where Xeomin is so different.

Xeomin varies from all currently available products in that it is a “naked” toxin. While it contains the same central core protein, it brings with it no accessory proteins. What’s the big deal, you ask? Each time we are exposed to proteins, our bodies potentially can react to these specific proteins and develop antibodies. A good example of this is when we get a flu shot. In the case of the flu, it’s great that we develop antibodies. But in the case of a neuromodulator, when we develop antibodies we effectively develop immunity and so the product becomes less and less effective until it simply doesn’t work. And for that reason investigators are looking into whether or not Xeomin may be a more effective option in the long run than Botox. So far, this has not been proven in the lab nor has it been seen among European injectors who have had access to all three products for several years prior to their approval in the states. As such, only time will tell.

Xeomin will most likely be priced similar to its counterparts and so don’t look for tremendous cost savings. Like any injectable, many practitioners will probably offer incentives early on to introduce the new product to their patients but, in the long run, treatment costs will most likely even out.

As with any injectable, results are only as good as the person behind the needle. Look for a well-trained professional specifically skilled in this area that listens to your needs but is honest about anticipated outcome. As a national trainer, I have seen price points all across the board for these products and should emphasize that price should always be the last determining factor in who performs your injections. Remember, these results can last several months and achieve dramatic improvements in facial aging when performed correctly. The right product in the right hands is the best equation for a good outcome.

To introduce Xeomin to our clients, we will be offering a special two days-only incentive of $8.50 per unit. On December 15th and December 22nd, 2011. After this, our pricing will be the same as Botox. Come see what the buzz is all about and learn more about how to look your very best with minimal to no down-time. Please call my Denver Plastic Surgery office to schedule your treatment today. Space is limited and on a first-come basis.

Visualize your NEW LOOK in 3D NOW

START NOW
Natrelle® Breast Implants
IMPORTANT SAFETY INFORMATION

Breast implants are not lifetime devices. The longer patients have them, the greater the chance they will develop complications, which may require more surgery. Breast implants have been associated with a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Some patients have died from BIA-ALCL. Patients have also reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others.

Natrelle® Breast Implants are for breast augmentation and revision surgery in women at least 22 years old for silicone-filled implants and women at least 18 years old for saline-filled implants.

You should not get breast implants if you currently have an active infection, untreated breast cancer or precancer, or are pregnant or nursing. Tell your doctor about any conditions you have, any medications you are taking, and any planned cancer treatments. Breast implantation is likely not a one-time surgery.

Having implants removed and not replaced may lead to permanent cosmetic changes of the breasts. Breast implants may affect breastfeeding. Gel implants may rupture without symptoms, so periodic imaging after surgery is recommended.

Key complications are reoperation, implant removal, implant rupture, implant deflation with saline-filled implants, and severe capsular contracture.

Talk to your doctor for more information.

The use of Natrelle® Breast Implants is restricted to licensed physicians who provide information to patients about the risks and benefits of breast implant surgery.

Visualize your
NEW LOOK in 3D NOW!

Start now
START NOW
Natrelle® Breast Implants
IMPORTANT SAFETY INFORMATION

Breast implants are not lifetime devices. The longer patients have them, the greater the chance they will develop complications, which may require more surgery. Breast implants have been associated with a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Some patients have died from BIA-ALCL. Patients have also reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others.

Breast implants are not lifetime devices. The longer patients have them, the greater the chance they will develop complications, which may require more surgery. Breast implants have been associated with a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Some patients have died from BIA-ALCL. Patients have also reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others.

Breast implants are not lifetime devices. The longer patients have them, the greater the chance they will develop complications, which may require more surgery. Breast implants have been associated with a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Some patients have died from BIA-ALCL. Patients have also reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others.

Breast implants are not lifetime devices. The longer patients have them, the greater the chance they will develop complications, which may require more surgery. Breast implants have been associated with a cancer of the immune system called breast implant–associated anaplastic large cell lymphoma (BIA-ALCL). Some patients have died from BIA-ALCL. Patients have also reported a variety of systemic symptoms such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others.